| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be8d9e2e752c2fa8e3a8b69fc3abf2c9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate |
2022-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd179921e3ec6d80186cd23f9d651199
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_177540df05ed395d026d7ebb86cca514
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9e52190d5cd4094b3a944119606c45 |
| publicationDate |
2022-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022194109-A1 |
| titleOfInvention |
Complex for treating optic nerve disease, and preparation method therefor and use thereof |
| abstract |
Disclosed is a complex tFNA-miR22 for treating optic nerve disease, which complex is composed of tetrahedral DNA and miR-22 according to a molar ratio of 1: (1-4). The tFNA-miR22 can effectively inhibit apoptosis of retinal ganglion cells and promote the release of a brain-derived neurotrophic factor (BDNF), thereby achieving a good protection effect for the retinal ganglion cells. The tFNA-miR22 is used for preparing optic nerve protection drugs, the treatment of neurodegenerative optic nerve diseases including glaucoma is facilitated, and the tFNA-miR22 has very good application prospects. |
| priorityDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |